Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Another huge quarter for biotech flotations
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.
More biotechs test the third way to market
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
For a quick exit, head to the stock market
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.
Curevac rides the Covid wave
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
With a following wind JW looks to go public
The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.
A baptism of fire for listing medtechs
Medtechs going public in 2020 raised a decent amount of cash, but have had a turbulent time of it since.
